Dear Valued Visitor,

We have noticed that you are using an ad blocker software.

Although advertisements on the web pages may degrade your experience, our business certainly depends on them and we can only keep providing you high-quality research based articles as long as we can display ads on our pages.

To view this article, you can disable your ad blocker and refresh this page or simply login.

We only allow registered users to use ad blockers. You can sign up for free by clicking here or you can login if you are already a member.

Hedge Funds Are Buzzing About GW Pharmaceuticals PLC- ADR (GWPH)

Page 1 of 2

Looking for high-potential stocks? Just follow the big players within the hedge fund industry. Why should you do so? Let’s take a brief look at what statistics have to say about hedge funds’ stock picking abilities to illustrate. The Standard and Poor’s 500 Index returned approximately 7.6% in the 12 months ending November 21, with more than 51% of the stocks in the index failing to beat the benchmark. Therefore, the odds that one will pin down a winner by randomly picking a stock are less than the odds in a fair coin-tossing game. Conversely, best performing hedge funds’ 30 preferred mid-cap stocks generated a return of 18% during the same 12-month period. Coincidence? It might happen to be so, but it is unlikely. Our research covering a 17-year period indicates that hedge funds’ stock picks generate superior risk-adjusted returns. That’s why we believe it is wise to check hedge fund activity before you invest your time or your savings on a stock like GW Pharmaceuticals PLC- ADR (NASDAQ:GWPH).

Is GW Pharmaceuticals PLC- ADR (NASDAQ:GWPH) an excellent investment today? Investors who are in the know are in an optimistic mood. The number of long hedge fund bets jumped up by 7 lately. The level and the change in hedge fund popularity aren’t the only variables you need to analyze to decipher hedge funds’ perspectives. A stock may witness a boost in popularity but it may still be less popular than similarly priced stocks. That’s why at the end of this article we will examine companies such as Ariad Pharmaceuticals, Inc. (NASDAQ:ARIA), BlackRock Credit All Inc Trust IV (NYSE:BTZ), and Grupo Financiero Galicia S.A. (ADR) (NASDAQ:GGAL) to gather more data points.

At Insider Monkey, we’ve developed an investment strategy that has delivered market-beating returns over the past 12 months. Our strategy identifies the 100 best-performing funds of the previous quarter from among the collection of 700+ successful funds that we track in our database, which we accomplish using our returns methodology. We then study the portfolios of those 100 funds using the latest 13F data to uncover the 30 most popular mid-cap stocks (market caps of between $1 billion and $10 billion) among them to hold until the next filing period. This strategy delivered 18% gains over the past 12 months, more than doubling the 8% returns enjoyed by the S&P 500 ETFs.

medication, pharmacist, shelf, care, pharmaceutical, medical, day, drug, clinic, medicament, drugstore, treatment, ill, smiling, medicine, pharmaceutics, of, hospital,

wavebreakmedia/Shutterstock.com

Hedge fund activity in GW Pharmaceuticals PLC- ADR (NASDAQ:GWPH)

At Q3’s end, a total of 24 of the hedge funds tracked by Insider Monkey were bullish on this stock, a 41% jump from the previous quarter. With the smart money’s capital changing hands, there exists a few notable hedge fund managers who were increasing their stakes meaningfully (or already accumulated large positions).
GWHR
According to publicly available hedge fund and institutional investor holdings data compiled by Insider Monkey, Scopia Capital, managed by Matt Sirovich and Jeremy Mindich, holds the biggest position in GW Pharmaceuticals PLC- ADR (NASDAQ:GWPH). Scopia Capital has a $250.2 million position in the stock, comprising 4.4% of its 13F portfolio. On Scopia Capital’s heels is Deerfield Management, led by James E. Flynn, holding a $133.9 million position; 6.2% of its 13F portfolio is allocated to the company. Remaining peers with similar optimism encompass Andreas Halvorsen’s Viking Global, Jeremy Green’s Redmile Group and Kris Jenner, Gordon Bussard, and Graham McPhail’s Rock Springs Capital Management.

Page 1 of 2
Loading Comments...